EUVIMEDOpdag EUVIMED
Systematische ÜbersichtFallberichtOpen access · CC BY-NC-ND 4.0

Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review

Brian D Adkins iD, Daniel K Noland, Tamra Slone, Arhanti Sadanand

Journal of Clinical Apheresis · 2024

DOI: 10.1002/jca.22116 ↗

At a glance

Systematische Übersicht in Journal of Clinical Apheresis, 2024. Written by Brian D Adkins and 3 co-authors. Institution: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Gemtuzumab, Plasma Exchange, Hemoglobins. 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Gemtuzumab ozogamicin (GO) is a CD33 monoclonal antibody‐drug conjugate currently in use to treat myeloid malignancies. A unique adverse effect of this medication is destruction of CD33 positive macrophages resulting in reduced clearance of free hemoglobin leading to grossly red plasma. This build‐up of free hemoglobin can potentially lead to end organ damage and prevent performance of clinically necessary laboratory evaluation. We present a case of a pediatric patient who developed this adverse effect and was successfully treated with therapeutic plasma exchange (TPE). We also present results from a systematic review of the medical literature and share data from a query of the United States Food and Drug Administration (FDA) Adverse Event Reporting system for GO‐related hemoglobin scavenging impairment. Among reported cases, patients undergoing TPE and those receiving steroids had improved outcomes. Practitioners should be aware of this rare drug side‐effect and the potential utility of TPE for these patients.

Subjects

MeSH terms (MEDLINE)

GemtuzumabPlasma ExchangeHemoglobinsHumansSialic Acid Binding Ig-like Lectin 3MaleAminoglycosidesFemaleAntibodies, Monoclonal, Humanized

Author keywords

free hemoglobingemtuzumabhemoglobin scavengingtherepeutic plasma exchange

Substances

GemtuzumabHemoglobinsSialic Acid Binding Ig-like Lectin 3AminoglycosidesAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Children's Health System, Dallas, Texas, USA.
  • Division of Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

ORCID profiles: Brian D Adkins

Cite

APA

Adkins, B. D., Noland, D. K., Slone, T., & Sadanand, A. (2024). Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22116

Vancouver

Adkins BD, Noland DK, Slone T, Sadanand A. Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review. Journal of Clinical Apheresis. 2024. doi:10.1002/jca.22116

BibTeX
@article{Adkins2024,
  author = {Adkins, Brian D and Noland, Daniel K and Slone, Tamra and Sadanand, Arhanti},
  title = {Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review},
  journal = {Journal of Clinical Apheresis},
  year = {2024},
  doi = {10.1002/jca.22116}
}
Start for free →